Arcutis raises 2026 guidance after ZORYVE revenue jumps 59%
Arcutis Biotherapeutics has reported second-quarter 2026 net product revenue of $129.9 million, a 59% increase on the same period last year and a 23% sequential rise on the first quarter, driven by demand growth across its ZORYVE franchise of topical PDE4 inhibitors. On the back of those results, the Westlake Village, California-based company raised its full-year 2026 net product sales guidance to $525 million–$540 million, up from the prior range of $480 million–$495 million.
The company also swung to a net profit of $15.0 million in the quarter, compared with a net loss of $15.9 million in Q2 2025, as revenue growth outpaced an increase in operating expenses. Selling, general, and administrative costs rose to $82.1 million from $69.2 million a year earlier, reflecting continued investment in the dermatology sales force.
Pipeline and regulatory progress
Arcutis secured its seventh FDA approval since 2022 during the quarter, when the regulator cleared a supplemental NDA for ZORYVE cream 0.3% to cover plaque psoriasis in children from two years of age. That label extension broadens the addressable population for what is already the company's largest individual product line by revenue, which contributed $35.3 million in the quarter.
On the regulatory horizon, the FDA accepted an sNDA for ZORYVE cream 0.05% to cover mild to moderate atopic dermatitis in infants aged three to 24 months, setting a PDUFA target action date of 23 February 2027. If approved, that would extend the franchise into one of the youngest and most underserved patient populations in dermatology.
The company also completed enrolment in a Phase 2 proof-of-concept study of ZORYVE foam 0.3% for vitiligo, with topline results and a decision on programme advancement expected in the fourth quarter of 2026. A separate Phase 2 study in hidradenitis suppurativa remains open to enrolment, with a readout anticipated in the first quarter of 2027. Earlier-stage work continues on ARQ-234, a fusion protein acting as a selective checkpoint agonist of the CD200 receptor, currently in a Phase 1a/1b first-in-human study in healthy volunteers and adults with moderate to severe atopic dermatitis.
Market context
The non-steroidal topical dermatology segment has expanded materially in recent years. Arcutis competes with Eli Lilly's lebrikizumab and Pfizer's abrocitinib in atopic dermatitis, while the psoriasis space includes both established biologics from AbbVie and Novartis and newer oral options. Arcutis's positioning rests on the tolerability and formulation breadth of roflumilast, which avoids the systemic exposure associated with JAK inhibitors. The paediatric label extensions are commercially meaningful: children represent a significant undertreated proportion of both psoriasis and atopic dermatitis populations, and branded non-steroidal options in younger age groups have historically commanded strong payer support.
The company also flagged two commercial access initiatives: a virtual health platform connecting patients with board-certified dermatologists, and a partnership with an unnamed AI-enabled healthcare platform designed to streamline ZORYVE prescribing within provider workflows. Arcutis completed hiring of a dedicated primary care and paediatric sales team, expected to be fully deployed by the end of August.
Frank Watanabe, president and chief executive, said Arcutis is "well positioned to drive continued growth and momentum through the second half of 2026," pointing to the sales force investment and patient access initiatives as key drivers. The company held $238.9 million in cash, cash equivalents, restricted cash, and marketable securities at 30 June 2026, and generated $12.6 million of operating cash flow in the quarter.